Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA damage repair pathway-deficient cells are cells that have lost or have impaired function in one or more of the cellular mechanisms responsible for detecting and repairing DNA damage. These deficiencies can arise from mutations, deletions, or epigenetic silencing of genes encoding key proteins in the various DNA repair pathways. Such defects compromise genome integrity and are associated with increased cancer risk, progression, and altered responses to therapy. They can be targeted therapeutically through synthetic lethality or by exploiting their increased sensitivity to specific genotoxic agents.
Synthetic lethality, chemosensitization, radiosensitization, immune checkpoint blockade
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA Damage Repair Pathway-Deficient Cells (DDR-deficient cells).